Everything about Tyrosinase-IN-12
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main demo targets were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis i